|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
2.49/5.51
|
企业价值
2.16B
|
资产负债 |
每股账面净值
44.52
|
现金流量 |
现金流量率
0.04
|
损益表 |
收益
131.31M
|
每股收益
9.52
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/12/25 01:45 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license andmilestone payments, and sale of its trademarked Captisol material. |